C4 Therapeutics, Inc. (CCCC) stock
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3019% above fair value
$2.77−0.12 (-4.15%)
Close on Nov 12, 2026Market cap $340.78MP/E –Yield –
C4 Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
C4 Therapeutics's operating margin for the twelve months ending Sep 30, 2026 was -315.9%. For fiscal 2025 it was -320.5%, against -336.1% the year before. The highest annual figure on record is -179.4% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -320.5% | +15.6 |
| FY2024 | Dec 31, 2024 | -336.1% | +333.7 |
| FY2023 | Dec 31, 2023 | -669.8% | −253.3 |
| FY2022 | Dec 31, 2022 | -416.6% | −237.2 |
| FY2021 | Dec 31, 2021 | -179.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -290.5% | +16.0 |
| Q2 FY2026 | Jun 30, 2026 | -397.9% | +43.1 |
| Q1 FY2026 | Mar 31, 2026 | -451.6% | −48.7 |
| Q4 FY2025 | Dec 31, 2025 | -210.1% | +518.3 |
| Q3 FY2025 | Sep 30, 2025 | -306.4% | −122.6 |
| Q2 FY2025 | Jun 30, 2025 | -441.0% | −262.4 |
| Q1 FY2025 | Mar 31, 2025 | -402.9% | +657.3 |
| Q4 FY2024 | Dec 31, 2024 | -728.4% | +419.3 |
| Q3 FY2024 | Sep 30, 2024 | -183.9% | +67.3 |
| Q2 FY2024 | Jun 30, 2024 | -178.6% | +1231.6 |
| Q1 FY2024 | Mar 31, 2024 | -1060.2% | −96.4 |
| Q4 FY2023 | Dec 31, 2023 | -1147.7% | +194.0 |
| Q3 FY2023 | Sep 30, 2023 | -251.2% | +229.9 |
| Q2 FY2023 | Jun 30, 2023 | -1410.2% | −1212.3 |
| Q1 FY2023 | Mar 31, 2023 | -963.8% | −553.9 |
| Q4 FY2022 | Dec 31, 2022 | -1341.7% | −1265.8 |
| Q3 FY2022 | Sep 30, 2022 | -481.0% | −195.7 |
| Q2 FY2022 | Jun 30, 2022 | -197.9% | +28.2 |
| Q1 FY2022 | Mar 31, 2022 | -409.8% | – |
| Q4 FY2021 | Dec 31, 2021 | -76.0% | – |
| Q3 FY2021 | Sep 30, 2021 | -285.3% | – |
| Q2 FY2021 | Jun 30, 2021 | -226.1% | – |
See a number that looks wrong?